Abstract
Steroid-refractory graft-vs-host disease (SR-GVHD) remains a significant cause of mortality after allogeneic hematopoietic cell transplantation (HCT), and the trajectory of treatment response for that vary. In our case series, we introduced six cases experiencing SR-GVHD who achieved better disease control after applying ruxolitinib (RUX). Of the six cases, five of them achieved symptoms-free while one of them, unfortunately, died of invasive fungal infection. Three alive cases were weaned off the RUX treatment successfully, while the remaining were on a medication tapering program. We demonstrated mixed efficacy in patients with SR-GVHD, suggesting that the RUX add-on may be a useful therapeutic adjunct in combination with other immunosuppressants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
